Navigation Links
OncoMed Pharmaceuticals Announces FDA Clearance to Commence Phase 1 Testing of Anti-Cancer Stem Cell Therapeutic OMP-18R5
Date:4/28/2011

REDWOOD CITY, Calif., April 28, 2011 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells or tumor-initiating cells, today announced that the FDA has accepted an IND filing for OMP-18R5, which allows OncoMed to commence Phase 1 clinical testing.  

OMP-18R5 is a monoclonal antibody that binds selected receptors in the Wnt signaling pathway and is the first antibody to specifically block these targets to enter human studies.  The Phase 1 clinical trial of OMP-18R5 is a single-agent study designed to evaluate the safety of escalating doses of OMP-18R5 in patients with advanced solid tumors.  The study will also assess pharmacokinetics, biomarkers and initial evidence of efficacy.  The Phase 1 trial is being conducted at leading U.S. cancer drug development centers.  Preclinical studies have shown that OMP-18R5 decreases the frequency of tumor-initiating cells across a variety of tumor types.  

"The acceptance from the FDA to begin clinical testing for OMP-18R5 represents an important milestone for OncoMed.  OMP-18R5 is our first Wnt pathway program cleared to begin clinical trials, and we now have three novel agents in the clinic in multiple clinical trials," said Paul Hastings, President and Chief Executive Officer of OncoMed Pharmaceuticals.  "We are excited to continue building and advancing our rich pipeline of first-in-class anti-cancer stem cell therapeutics with the potential to dramatically transform cancer treatment by directly targeting tumor-initiating cells."  

OMP-18R5 is part of OncoMed's collaboration with Bayer HealthCare Pharmaceuticals and its advancement to the clinic triggers a $20M milestone payment from Bayer to OncoMed.  In June 2010, OncoMed and Bayer entered into a broad strategic alliance valued at up to $387.5M per program to develop cancer stem cell antibody and protein therapeutics targeting the Wnt signa
'/>"/>

SOURCE OncoMed Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
2. SynCo Expands Agreement with OncoMed Pharmaceuticals to Manufacture Cancer Stem Cell Antibodies
3. Bayer and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
4. OncoMed Pharmaceuticals Awarded Five Therapeutic Discovery Project Grants Totaling $1.2 Million
5. OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5
6. OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: ... the Office of Fair Trading (OFT) approval condition to the announced ... (NASDAQ: VPHM).   As a result of the waiver, ... expects to complete the tender offer on January 24, 2014 following ...
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb the ... ambulances and other transport vehicles, an advanced and portable UV germicidal ... for the first time. In order to prevent ... deadly pathogens, West Palm Beach Fire Rescue ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness ... Fitness Center by the Medical Fitness Association, a non-profit ... achieve their full potential. The Cadence Fitness & Health ... western suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... An alarming study,that appeared in the March 1, ... American Cancer Society), reports that one-third of,women taking ... treatment tamoxifen citrate, discontinue therapy early.(1), According to ... issue that may negatively affect treatment efficacy.,While tamoxifen ...
... of one notorious,childhood disease, poliovirus, could be used ... neuroblastoma. In the March 15,issue of Cancer Research, ... -- or non-virulent -- form of poliovirus,is effective ... mice had been previously vaccinated against the virus. ...
Cached Medicine Technology:One-Third of Patients Discontinue Common Breast Cancer Therapy 2One-Third of Patients Discontinue Common Breast Cancer Therapy 3Researchers Use Poliovirus to Destroy Neuroblastoma Tumors in Mice 2Researchers Use Poliovirus to Destroy Neuroblastoma Tumors in Mice 3Researchers Use Poliovirus to Destroy Neuroblastoma Tumors in Mice 4
(Date:4/17/2014)... the most popular vaccine brands for children may not ... overlooking some cost factors when choosing vaccines, driving the ... according to a new study by University of Illinois ... be driven by numerous factors," says Sheldon H. Jacobson, ... computer science and of mathematics at the U. of ...
(Date:4/17/2014)... California, San Diego School of Medicine report that older ... recent major loss are more likely to be compassionate ... is published in this month,s issue of the ... behaviors are associated with better health and well-being as ... to improve the outcomes of individuals whose deficits in ...
(Date:4/17/2014)... MD, was recently invited to submit a review ... Microbiology , one of the world,s foremost scientific ... specialist, and chair of the Department of Pediatrics ... analyzed the epidemiology and microbiology of co-infections during ... as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... , , ORLANDO, Fla., ... new report today at its annual convention in Toronto acknowledging ... comes to dealing with conflicts between religious beliefs and same-sex ... conflict with their sexuality and faith, says this report acknowledges ...
... ... , ... Atlanta, GA (Vocus) August 5, 2009 -- CareFirst BlueCross BlueShield (CareFirst) today announced that ... in National Account Service Company LLC (NASCO), joining the Blue Cross and Blue Shield ...
... , , BOSTON, Aug. 5 ... management solutions, today reported unaudited financial results for the second quarter ended June ... ) , , Q2 Financial Highlights ... second quarter of 2009 was $23.5 million, compared to $13.6 million for the ...
... , , HARRISBURG, Pa., Aug. ... of Massage Therapy began drafting preliminary regulations that will protect ... Commonwealth Pedro A. Cortes. , , "By ... and training, we can provide the best and most up-to-date ...
... , , ST. PAUL, Minn., Aug. ... Extreme Makeover: Home Edition (EMHE) premieres its seventh season ... be among a select group as a Designated Charity for an ... Duluth/Superior area. The EMHE episode, air date to be announced at ...
... simply a marker for obesity is unclear , , WEDNESDAY, ... activates sex hormones throughout the body may also predict those ... study finds. , The protein, called sex hormone-binding globulin (SHBG), ... Researchers suspect it also plays a role in the development ...
Cached Medicine News:Health News:APA Releases Report on Sexuality Debate 2Health News:APA Releases Report on Sexuality Debate 3Health News:CareFirst Joins Partnership of Blues Plans as Owner of NASCO 2Health News:CareFirst Joins Partnership of Blues Plans as Owner of NASCO 3Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 2Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 3Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 4Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 5Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 6Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 7Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 8Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 9Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 10Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 11Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 12Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 13Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 14Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 15Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 16Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 17Health News:State Regulation of Massage Therapy Will Improve Public Health, Safety 2Health News:State Regulation of Massage Therapy Will Improve Public Health, Safety 3Health News:Memorial Blood Centers Joins Extreme Makeover: Home Edition As Designated Charity 2Health News:Memorial Blood Centers Joins Extreme Makeover: Home Edition As Designated Charity 3Health News:Sex Hormone Protein May Predict Type 2 Diabetes 2Health News:Sex Hormone Protein May Predict Type 2 Diabetes 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: